YALDOO LAITH L

Director Laith Yaldoo buys 1,543 shares of ZIVO at $9.72; stock down -56.0% from 52-week high, unprofitable company with 468.6% annual revenue growth.

Director Laith Yaldoo purchased 1,543 shares at $9.72 on 2026-02-27, raising his holdings to 583.6K shares. The purchase occurs in a weak near-term context: the stock has declined 11.9% over the past 30 days and trades 56.0% below its 52-week high of $21.00. Examining his same-ticker history at ZIVO, Yaldoo has made 5 prior purchases, with a 90-day win rate of only 1 of 3 measurable outcomes—a low success rate. The company remains fundamentally challenged, posting a net loss of $1.0M against quarterly revenue of $65.6K, though annual revenue growth of 468.6% indicates potential scaling. The small transaction size (0.3% of post-transaction holdings) and recurring buy pattern despite poor historical returns at this ticker suggest routine accumulation rather than a conviction-driven entry point during market stress.

Director Yaldoo Laith L buys 2,434 shares of ZIVO at $10.27, now -54.0% from 52-week high; holds 582.1K shares post-trade.

Director Yaldoo purchased 2,434 shares at $10.27 on 2026-02-10, adding modestly to an already substantial 582.1K-share position. The timing relative to the stock's 52-week range is notable: the purchase occurred at $10.27, which is now -54.0% from the 52-week high of $21.49, suggesting the director bought into a substantially depressed price. However, his prior trades at ZIVO show a troubling pattern—of 3 prior measurable 90-day outcomes at this ticker, 0 were well-timed (all showed negative 90-day returns: -9.3%, -22.8%, and -43.4%), indicating a consistent pattern of buying before further declines. The company's fundamentals remain challenging: revenue is only $65,625.00 for the latest quarter against a net loss of $-1,033,056.00, with market cap of $38,419,318.60. While annual revenue growth reached +468.6%, unprofitability persists, creating uncertainty about the business's sustainability and the rationale behind continued accumulation.

Director Yaldoo buys 1,766 shares at $8.49 (down 54.6% from 52-week high); prior ZIVO buys show 0 of 4 were well-timed at 90 days, 3-insider cluster.

Yaldoo Laith L, a director, purchased 1,766 shares of ZIVO at $8.49 on 2026-01-14 while the stock trades 54.6% below its 52-week high of $21.49. His SAME-TICKER HISTORY shows a concerning pattern: of his 4 prior measurable ZIVO buy trades, none achieved positive 90-day returns, with outcomes ranging from -9.3% to -43.4%. The current purchase occurs within a cluster of 3 other insider buys in the past 14 days, but his track record at this specific ticker does not support a view that he times his purchases effectively—4 of 4 prior attempts lost value over the 90-day window. The company reported revenue of $65.6K and a net loss of $1.0M in the latest quarter, with full-year profitability also negative, raising questions about the operational foundation for the stock's recovery.

Director Yaldoo purchases 2,777 shares of ZIVO at $9.00; stock down -39.1% in 90 days, 0 of 3 prior same-ticker buys well-timed.

Director Laith L Yaldoo purchased 2,777 shares at $9.00 on 2025-11-28, raising holdings to 577,872 shares. The stock has declined significantly since the transaction, with current price at $10.35 representing a -26.1% decline over the past 30 days and -39.1% over 90 days from a 52-week high of $22.10. Examining same-ticker execution history reveals a consistent pattern of poor timing: the director's 5 prior trades at ZIVO show 0 of 3 measurable buys achieved positive 90-day returns, with prior purchases on this stock returning -9.3%, -31.5%, and -31.5% over 90 days. The company's fundamentals show recent quarterly revenue of $65,625.00 against a net loss of $-1,033,056.00, with market capitalization of $40,246,958.25, indicating structural profitability challenges. This purchase adds to a pattern of accumulation into a declining asset without evident positive outcomes from prior timing decisions at this ticker.

Director Yaldoo purchased 1,659 shares of ZIVO at $12.05; stock down 40.3% from 52-week high; cluster of 2 other insiders also bought within 14 days.

Director Laith L Yaldoo purchased 1,659 shares at $12.05, adding modestly to holdings already at 573,436 shares. The stock currently trades at $13.20, down 40.3% from its 52-week high of $22.10, and has declined 5.8% over the past 30 days. At the same ticker, Yaldoo's prior four measurable trades show mixed results: one was well-timed (the October 2024 buy returned +34.4% in 30 days and +13.4% in 90 days), but three underperformed, with the most recent prior buy on June 13, 2025 returning -5.8% at 30 days and -9.3% at 90 days. The company posted $53.4K in latest quarterly revenue but reported a -$1.6M net loss and remains unprofitable on a full-year basis, despite 468.6% annual revenue growth. A cluster of 2 other insiders also purchased within the past 14 days, suggesting some coordinated conviction at this price level. The transaction's modest size relative to existing holdings and the insider's historically inconsistent timing at this ticker merit close attention to whether this buy reflects genuine operational confidence or simply accumulation at a depressed price.

Director Laith Yaldoo buys 15,322 shares of Zivo at $15.99; stock down 45.6% from 52-week high, down 31.3% in 30 days.

Laith Yaldoo, a director of Zivo Bioscience, purchased 15,322 shares for $244,998.78 on 2025-09-30 at $15.99 per share, increasing his holdings by 2.7% to 573,436 shares. The transaction occurs in a deteriorated context: the stock trades at $12.03, down 45.6% from its 52-week high of $22.10 and down 31.3% over the prior 30 days. The company faces fundamental headwinds—while annual revenue growth reached +468.6%, this masks minimal absolute revenue of $53,400.00 in the latest quarter and a negative net income of $-1,640,232.00, with the company unprofitable over its most recent full fiscal year. Yaldoo's own cross-ticker track record shows 4 prior buys with an average 90-day return of -14.7%, and his same-ticker history at Zivo includes only 1 well-timed buy (at the 90-day mark) out of 4 prior trades, suggesting limited accuracy in timing this particular security. The purchase appears discretionary and open-market, yet takes place during significant price weakness and amid material operational losses.

Director Yaldoo buys 3,488 ZIVO shares at $14.33 (+$50.0K); stock down -27.8% in 30d, -41.2% from 52-week high; prior two ZIVO buys both down -31.5% at 90d.

Director Laith L Yaldoo purchased 3,488 shares at $14.33 on 2025-06-13 for a total value of $49,983.04, increasing his holdings by 0.6% to 558,114 shares. At his transaction price of $14.33, the current price of $13.00 represents a mark-to-market loss of approximately 9% on this specific purchase. His prior trading history at ZIVO is notably unfavorable: his two prior buys on 2025-01-22 at this ticker both recorded 90-day returns of -31.5%, while his cross-ticker track record shows a 90-day win rate of only 33.33%. The company's fundamentals remain challenged, reporting zero revenue in the latest quarter with a net loss of $4,211,188.00, though annual revenue growth reached +468.6%. The stock has declined -27.8% in the 30 days since this purchase and sits -41.2% from its 52-week high, suggesting ongoing downward momentum since the transaction date.

Director Yaldoo buys 10,080 shares at $17.53 in two transactions; stock down 28.6% from 52-week high, now trading $15.77

YALDOO LAITH L purchased 10,080 shares ($176,682.24) in two separate transactions at $17.53 on 2025-01-22, increasing holdings from 544,546 to 554,626 shares (+1.9% net change). The purchase occurred as ZIVO traded 28.6% below its 52-week high and down 20.4% over the prior 30 days, while the company reports quarterly revenue of $31,500 and an annual net loss of $2,268,597. His prior buy at this ticker on 2024-10-16 generated positive 90-day returns (+13.4%), consistent with his cross-ticker track record showing 100% win rate on 1 prior buy (avg 90d return +13.4%); however, the current transaction's timing relative to subsequent price action remains unresolved. The fundamental picture shows material unprofitability despite revenue growth of +468.6% year-over-year, setting a context of high volatility and financial stress typical of early-stage biotech.

Director Yaldoo purchases 3,133 shares of ZIVO at $15.96; stock up 46% in 30 days, company unprofitable with $0 revenue.

Director Laith L Yaldoo purchased 3,133 shares at $15.96, increasing holdings to 533,424 shares (+0.6% net change). The purchase occurs in a context of exceptional recent volatility: the stock has risen 46.0% over 30 days and 138.3% over 90 days, while trading within a 52-week range of $0.48–$20.50. However, the company's fundamentals remain extremely weak: revenue for the latest quarter is $0.00, net income is $-8,236,368.00, and the company was unprofitable over its most recent full fiscal year. The director's small incremental position increase during a period of sharp price appreciation in a cash-burn biotech requires careful scrutiny into the underlying operational drivers of the rally and the company's path to revenue.